Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity - Liu, Yanhong; Gong, Liming; Feng, Jing; Xiao, Congcong; Liu, Chenfei; Chen, Bohan; Chen, Liqing; Jin, Mingji; Guan, Youyan; Gao, Zhonggao; Huang, Wei (Journal of nanobiotechnology, 2025)
Keywords: Animals; Anti-tumor immunotherapy; Axitinib; Axitinib - chemistry; Axitinib - pharmacology; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Cancer; Carcinoma, Renal cell; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - immunology; Cell Line, Tumor; Dosage and administration; Drug therapy; Drug therapy, Combination; Female; Humans; Immune checkpoint inhibition; Immune Checkpoint Inhibitors - pharmacology; Immune response; Immunosuppressive microenvironment; Immunotherapy; Kidney Neoplasms - drug therapy; Kidney Neoplasms - immunology; Liposomes - chemistry; Methods; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic - drug therapy; Oncology, Experimental; Renal cell carcinoma; RNA, Small Interfering - pharmacology; Tumor Microenvironment - drug effects; Tumors; Vascular normalization; China; Immune checkpoint inhibition; Anti-tumor immunotherapy; Vascular normalization; Renal cell carcinoma; Immunosuppressive microenvironment